Mammary Cell News Volume 13.26 | Jul 15, 2021

    0
    72







    2021-07-15 | MCN 13.26


    Mammary Cell News by STEMCELL Technologies
    Vol. 13.26 – 15 July, 2021
    TOP STORY

    Morphological Screening of Mesenchymal Mammary Tumor Organoids to Identify Drugs That Reverse Epithelial-Mesenchymal Transition

    Researchers reported that cells derived from claudin-low mammary tumors, a mesenchymal subtype of TNBC, exhibited a distinctive organoid structure with extended “spikes” in 3D matrices.
    [Nature Communications]

    Full Article

    Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart
    PUBLICATIONSRanked by the impact factor of the journal

    The HIF Target MAFF Promotes Tumor Invasion and Metastasis through IL11 and STAT3 Signaling

    Investigators identified v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (MAFF) as a potent regulator of tumor invasion without affecting cell viability, and demonstrated the oncogenic role of MAFF as an activator of the IL11/STAT3 pathways in breast cancer.
    [Nature Communications]

    Full Article

    Cell Line-Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

    Scientists used a network-based mathematical model to identify sensitivity regulators and drug combinations for the PI3Kα inhibitor alpelisib in ER+ PIK3CA mutant breast cancer. The combination of alpelisib and BH3 mimetics, e.g., MCL1 inhibitors, was experimentally validated in ER+ breast cancer cell lines.
    [Cancer Research]

    Abstract

    Combining CD47 Blockade with Trastuzumab Eliminates HER2-Positive Breast Cancer Cells and Overcomes Trastuzumab Tolerance

    Researchers leveraged human epidermal-growth-factor receptor-2 (HER2) overexpression to engage antibody-dependent cellular phagocytosis through a combination of trastuzumab and anti-CD47 macrophage checkpoint immunotherapy.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article

    A SNAI2-PEAK1-INHBA Stromal Axis Drives Progression and Lapatinib Resistance in HER2-Positive Breast Cancer by Supporting Subpopulations of Tumor Cells Positive for Antiapoptotic and Stress Signaling Markers

    Mesenchymal stem cells and cancer-associated fibroblasts expressed high PEAK1 protein levels and potentiated tumorigenesis, lapatinib resistance and metastasis of HER2-positive breast cancer cells in a Pseudopodium-Enriched Atypical Kinase One (PEAK1)-dependent manner.
    [Oncogene]

    Full Article

    Overexpression of PSMC2 Promotes the Tumorigenesis and Development of Human Breast Cancer via Regulating Plasminogen Activator Urokinase (PLAU)

    Loss-of-function study was used to evaluate the effects of Proteasome 26S subunit ATPase 2 (PSMC2) knockdown in cell proliferation, apoptosis and migration. Knockdown of PSMC2 suppressed breast cancer progression in vitro and in vivo.
    [Cell Death & Disease]

    Full Article

    Transcriptome Profiles of Stem-Like Cells from Primary Breast Cancers Allow Identification of ITGA7 as a Predictive Marker of Chemotherapy Response

    The authors identified the consistent transcriptome of primary breast cancer stem cells (BCSCs) shared across breast cancer subtypes, and examined the clinical relevance of ITGA7, one of the genes differentially expressed in BCSCs.
    [British Journal of Cancer]

    Full Article

    WNK1 Enhances Migration and Invasion in Breast Cancer Models

    Depletion or inhibition of WNK1 reduced migration of several breast cancer cell lines in wound healing assays and decreased invasion in collagen matrices.
    [Molecular Cancer therapeutics]

    Abstract

    The Novel STAT3 Inhibitor WZ-2-033 Causes Regression of Human Triple-Negative Breast Cancer and Gastric Cancer Xenografts

    WZ-2-033 significantly inhibited the proliferation, colony survival, migration, and invasion of TNBC cells and gastric cancer cells with aberrant signal transducer and activator of transcription 3 (STAT3) activation.
    [Acta Pharmacologica Sinica]

    Abstract

    New Insight into Long Non-Coding RNAs Associated with Bone Metastasis of Breast Cancer Based on an Integrated Analysis

    Investigators explored bone metastasis-related long non-coding RNAs (lncRNAs) in breast cancer and found that four LncRNA-mRNA pairs, including LOC641518-LEF1, may have played a central role in breast cancer bone metastasis.
    [Cancer Cell International]

    Full Article

    A scDb-Based Trivalent Bispecific Antibody for T-Cell-Mediated Killing of HER3-Expressing Cancer Cells

    Researchers developed bispecific antibodies for T-cell retargeting to HER3-expressing tumor cells, utilizing either a single-chain diabody format (scDb) with one binding site for HER3 and one for CD3 on T-cells or a trivalent bispecific scDb-scFv fusion protein exhibiting an additional binding site for HER3.
    [Scientific Reports]

    Full Article

    Deregulation of Protein Phosphatase 2A Inhibitor SET Is Associated with Malignant Progression in Breast Cancer

    SET, an endogenous inhibitor of protein phosphatase 2A, was overexpressed in all subtypes of invasive breast carcinoma tissues. Treatment with SET-targeted siRNAs reduced the motility of MCF-7 and MDA-MB-231 cells in transwell assay.
    [Scientific Reports]

    Full Article


    New human primary cancer-sourced blood products, immune cell subsets, and more. Click to view products.
    REVIEWS

    Microenvironmental Control of Cell Fate Decisions in Mammary Gland Development and Cancer

    The authors review how cell fate decisions are regulated by components of the microenvironment during mammary gland development and how pathological changes in the microenvironment can alter cell fates, leading to malignancy.
    [Developmental Cell]

    Abstract

    Endocrine Regulation of Cancer Stem Cell Compartments in Breast Tumors

    Scientists provide a comprehensive overview of the available evidence directly linking hormones to breast cancer stem cell biology.
    [Molecular and Cellular Endocrinology]

    Abstract

    INDUSTRY AND POLICY NEWS

    CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase II from Phase Ib

    CytoDyn, Inc., a biotechnology company developing leronlimab, a CCR5 antagonist, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic TNBC has advanced from Phase Ib to a Phase II trial.
    [CytoDyn, Inc.]

    Press Release

    TRIO Completes Enrolment for Phase II Giredestrant Early Breast Cancer Trial Ahead of Schedule

    Translational Research in Oncology (TRIO) announced enrollment completion in coopERA Breast Cancer, a Phase II clinical trial of giredestrant, an oral selective estrogen receptor degrader that showed encouraging tumor activity both alone and in combination with palbociclib in estrogen-receptor-positive metastatic breast cancer patients.
    [Translational Research in Oncology]

    Press Release

    FEATURED EVENT

    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    October 7 – 11, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate – Breast Cancer Research

    University of Pittsburgh – Pittsburgh, Pennsylvania, United States

    Scientist – Pathology and Laboratory Medicine

    Medical University of South Carolina – Charleston, South Carolina, United States

    Postdoctoral Researchers – Molecular Breast Cancer Epidemiology

    Karolinska Institutet – Stockholm, Sweden

    Research Fellow – Molecular Pharmacology & Experimental Therapeutics

    Mayo Clinic Health System – Rochester, Minnesota, United States

    Postdoctoral Research Fellow – Breast Cancer

    University of Michigan – Ann Arbor, Michigan, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter